Success Story: Advancing Translational Cancer Immunotherapy Research: NIW Approval Secured for a Project Scientist from Taiwan
Client’s Testimonial:
"I had a very positive experience working with the WeGreened team on my NIW petition. Throughout the process, they were professional, responsive, and provided clear guidance at every stage. Their well-prepared petition package reflected my research accurately and helped make the process much smoother than I expected. I truly appreciate their support and highly recommend WeGreened to researchers pursuing employment-based immigration."
On July 10th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Project Scientist in the field of Cancer Immunology (Approval Notice).
General Field: Cancer Immunology
Position at the Time of Case Filing: Project Scientist
Country of Origin: Taiwan
State of Residence at the Time of Filing: California
Approval Notice Date: July 10th, 2026
Processing Time: 2 months, 17 days (Premium Processing Requested)
Case Summary:
The client’s work focuses on investigating mechanistic and translational immunology approaches to interrogate immune regulatory mechanisms driving tumor persistence, therapeutic resistance, and treatment response in cancer. His research informs the development of immune-modulating and immunotherapeutic strategies to improve treatment durability and patient outcomes. At the time of filing, he was employed as a Project Scientist, responsible for designing experiments, analyzing data, and applying disease models to study cancer progression, with the goal of publishing original findings and advancing translational cancer immunology.
Research with National Importance
His research addresses a critical U.S. health challenge, as cancer incidence and mortality are projected to rise significantly in the coming decades. By uncovering molecular and cellular mechanisms underlying treatment resistance and response, his work supports the development of more effective therapies that can reduce mortality and improve patient care. His efforts align with U.S. federal priorities, including the Cancer Moonshot and NIH initiatives, promoting innovation in cancer prevention, immunotherapy, and public health outcomes.
Academic Contributions and Recognition
At the time of filing, the client had authored 11 peer-reviewed journal articles (6 first-authored), with a total of 243 citations, demonstrating independent reliance by other researchers. His work has contributed to understanding immune regulatory mechanisms and immune signaling pathways involved in disease progression and therapeutic responses, advancing both fundamental and translational immunology research.
He has conducted at least 3 peer reviews for authoritative journals in the field, reflecting his recognized expertise and leadership in cancer immunology research. These contributions provide strong evidence of his influence and impact in advancing translational cancer immunology and therapeutic development.
NIW Approval and Outlook
The I-140 NIW petition was filed on April 23rd, 2026, with direct Premium Processing, and approved on July 10th, 2026. The approval recognized the national importance of the client’s work, particularly his contributions to understanding immune regulatory mechanisms in cancer, therapeutic resistance, and immunotherapy strategies.
This outcome supports his continued efforts to advance translational cancer immunology, improve treatment outcomes for cancer patients, and contribute to innovative immunotherapeutic research in the United States. We congratulate him on this approval and wish him continued success in advancing public health and biomedical science.